Case report and literature review of severe adverse reactions following pucotenlimab treatment
New drug treatment linked to severe neurological reactions
This case report and literature review describes severe adverse reactions following treatment with pucotenlimab in a patient with advanced b…
A single patient facing advanced breast cancer experienced life-threatening neurological symptoms after receiving the drug pucotenlimab.
Observational study abstract reports AI RNA sequencing diagnostic accuracy in multiple sclerosis and neuromyelitis optica
Artificial Intelligence identifies early Multiple Sclerosis and separates it from others
This abstract describes an observational diagnostic accuracy study involving 997 participants.
Artificial Intelligence analyzes blood cells to tell early Multiple Sclerosis apart from healthy people and similar conditions like Neuromye…
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes
New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
Narrative review of animal models in neuromyelitis optica spectrum disorder pathogenesis
Animal Models Are Unlocking New Treatments for Rare Brain Disease
This narrative review examines animal models used to study neuromyelitis optica spectrum disorder pathogenesis.
Better animal models are helping scientists understand how NMOSD damages the brain, offering hope for new treatments for patients with few o…
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients
A New MS-Like Disease Drug Passes Its First Human Safety Test
This Phase 1b randomized, double-blind, placebo-controlled trial evaluated intravenous B001 in 22 patients with aquaporin-4 immunoglobulin G…
A new drug for a rare nerve disease that can cause blindness and paralysis passed its first human safety test with no severe side effects se…